GlaxoSmithKline Gains FDA Approval On Enlarged Prostate Treatment

Jun 20, 2008 (financialwire.net via COMTEX) -- GSK | Quote | Chart | News | PowerRating -- June 20, 2008 (FinancialWire) The U.S. Food and Drug Administration has approved GlaxoSmithKline's (NYSE: GSK | Quote | Chart | News | PowerRating) (Current Market Cap. US$116.09 Mil.) Avodart in combination with tamsulosin for the treatment of symptomatic enlarged prostate. The new indication reflects emerging research showing the combination of the two medicines treats the symptoms of enlarged prostate more effectively than either medicine alone.

Avodart already had been approved by the FDA for the treatment of enlarged prostate to improve urinary symptoms, reduce the risk of acute urinary retention, and reduce the risk of prostate-related surgery. Tamsulosin, an alpha-blocker, already had been indicated for the treatment of the signs and symptoms of enlarged prostate.

Common symptoms of enlarged prostate include nocturia, frequent and urgent urination, incomplete emptying, starting and stopping, and weak stream. If left untreated, enlarged prostate can lead to hospitalization for the inability to urinate or prostate surgery.

FinancialWire" is a fully independent, proprietary news wire service of Investrend Information (a division of Investrend Communications, Inc.). FinancialWire" news is written by professional journalists, dedicated to pure journalistic standards. FinancialWire" does not receive or accept any compensation from any individual or subject company (or representative thereof) for its news or opinions. All FinancialWire" news is available at http://www.financialwire.net . Please address any inquiries to feedback@financialwire.net .

Free annual reports for companies mentioned in the news are available at http://investrend.ar.wilink.com/?level=279 .

http://www.financialwire.net

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index